IPM Take
The annual flu vaccine is a useful antidote to the idea that preparedness begins when patients arrive.
By the time someone receives a 2027 Southern Hemisphere influenza vaccine, laboratories around the world will already have collected viruses, sequenced them, measured antigenic change, compared immunity, selected candidate strains and given manufacturers enough time to produce hundreds of millions of doses. The injection takes seconds. The surveillance architecture behind it runs all year.
Executive Summary
WHO has issued its recommendations for the viral composition of influenza vaccines for the 2027 Southern Hemisphere influenza season.
The recommendations are based on global virological and epidemiological surveillance conducted through the WHO Global Influenza Surveillance and Response System. Between February and August 2026, influenza A(H1N1)pdm09, A(H3N2) and influenza B viruses circulated globally, with differing patterns by region.
WHO recommends specific H1N1, H3N2 and B/Victoria-lineage viruses for egg-based vaccines and related but, for some components, distinct strains for cell-based, recombinant and nucleic-acid vaccines. WHO also reviewed zoonotic influenza viruses and selected new candidate vaccine viruses that could be used if a novel influenza threat required pandemic vaccine development.
Why it matters
- Manufacturers: Strain selection starts the production clock months before the next influenza season.
- Regulators: Vaccine composition needs to be translated into national approvals and lot-release processes without compressing manufacturing timelines.
- Surveillance networks: The accuracy of future vaccine decisions depends on countries continuing to collect and share representative virus samples now.
Influenza vaccine recommendations can look almost comically specific from the outside: a list of virus names, laboratory designations and manufacturing platforms published months before the season they are supposed to address. Hidden inside that list is one of the largest recurring exercises in predictive public health.
Influenza does not remain antigenically still long enough for the world to manufacture one vaccine and use it indefinitely. Viruses evolve, different lineages dominate in different periods, and the strain circulating when production begins may not be identical to the one driving disease when vaccination starts. WHO’s twice-yearly composition process is designed to manage that uncertainty with enough lead time for industry to manufacture at scale.
The 2027 Southern Hemisphere recommendation draws on surveillance between February and August this year. H1N1pdm09, H3N2 and influenza B viruses all circulated internationally, although their relative dominance differed between regions. Those patterns were combined with antigenic and genetic analysis and information about human immunity before WHO’s advisory process selected the recommended vaccine viruses.
Manufacturing technology adds another layer. Egg-based vaccines do not necessarily use exactly the same recommended H3N2 and B strains as cell-based, recombinant or nucleic-acid products because viruses can behave differently depending on how they are propagated. The recommendation therefore reflects not just viral evolution but the characteristics of the production platform that will ultimately deliver the vaccine.
This is a mature global system, but maturity should not be confused with certainty. Strain selection is fundamentally a forecast. The world is making a decision in September about which influenza variants are most likely to matter during a season months away. Some years the match is excellent; other years viral evolution reduces effectiveness. That does not make the process unsuccessful. It demonstrates why broad surveillance and rapidly adaptable vaccine technologies remain important.
The timetable also explains why influenza preparedness cannot wait for a surge. Manufacturers need enough time to create seed viruses or use platform-specific material, scale production, perform quality testing, package doses and supply multiple national markets. Regulators then need to complete their own requirements without creating unnecessary delay.
WHO’s assessment of zoonotic influenza viruses sits quietly alongside the seasonal recommendation and deserves attention. Candidate vaccine viruses are developed against animal influenza viruses with pandemic potential so manufacturing can begin faster if one acquires sustained human transmission. In that sense, the seasonal flu system doubles as a permanent pandemic-preparedness network.
This is what infectious-disease readiness looks like when it has been institutionalised: surveillance feeds decisions, decisions trigger manufacturing, manufacturing runs against a regulatory calendar and the entire process repeats before the previous season is fully forgotten.
The 2027 flu shot is not next year’s work.
It has already started.
